Coagulation function testing is a critical laboratory discipline that evaluates the blood's ability to clot properly, playing an essential role in preoperative screening, anticoagulant therapy monitoring, and diagnosis of bleeding or thrombotic disorders. This comprehensive guide covers the principles, sample requirements, test parameters, analytical methods, and clinical applications of modern coagulation testing performed in accredited laboratories worldwide.
Technical Overview
Coagulation function testing refers to a panel of laboratory assays designed to evaluate the hemostatic system—the complex physiological mechanism that prevents blood loss while maintaining vascular patency. Hemostasis involves three interrelated processes: primary hemostasis (platelet adhesion and aggregation), secondary hemostasis (the coagulation cascade leading to fibrin clot formation), and fibrinolysis (clot breakdown). Coagulation tests primarily assess secondary hemostasis by measuring the activity of plasma clotting factors and the time required for clot formation.
The coagulation cascade is classically divided into the intrinsic pathway (factors XII, XI, IX, VIII), the extrinsic pathway (tissue factor and factor VII), and the common pathway (factors X, V, II, and I, i.e., fibrinogen). Modern cell-based models of coagulation have refined this understanding, but the classical pathway framework remains the basis for interpreting routine tests such as the prothrombin time (PT) and activated partial thromboplastin time (APTT). Laboratories performing coagulation testing operate under quality frameworks such as ISO 15189 (medical laboratory accreditation) and follow harmonized methodological guidelines published by recognized clinical and laboratory standards organizations.
Because clotting factors are heat-labile and time-sensitive, coagulation testing demands rigorous pre-analytical control, including precise anticoagulant ratios, prompt centrifugation, and strict time limits between collection and analysis. Accurate results depend as much on sample integrity as on instrument performance, making pre-analytical standardization a central focus of any coagulation laboratory.
Testing Samples
Citrated Whole Blood and Platelet-Poor Plasma
The standard specimen for routine coagulation testing is venous blood collected into tubes containing 3.2% (0.109 mol/L) trisodium citrate at a 9:1 blood-to-anticoagulant ratio. Citrate chelates calcium ions, thereby preventing clot activation during collection and transport. For PT, APTT, thrombin time, and fibrinogen assays, the sample is centrifuged to obtain platelet-poor plasma (platelet count below 10 × 10⁹/L), which is then analyzed within a defined stability window—typically up to 4 hours for APTT at room temperature, and up to 24 hours for PT when refrigerated, depending on the validated laboratory protocol.
Citrated Platelet-Rich Plasma and Whole Blood for Point-of-Care Testing
Certain assays, such as platelet function studies, require platelet-rich plasma prepared by low-speed centrifugation. In parallel, point-of-care analyzers use non-anticoagulated fresh whole blood or citrated whole blood for tests such as the activated clotting time (ACT), widely used for monitoring high-dose heparin during cardiac surgery and interventional procedures.
Special Collection Considerations
Samples must be drawn before heparin flushes or transfusions, and lines should be avoided or adequately flushed to prevent heparin contamination and dilution. Under-filled tubes alter the anticoagulant ratio and falsely prolong clotting times. Gross hemolysis, clotted specimens, and samples from patients on direct oral anticoagulants (DOACs) may require specific interpretive adjustments or neutralization procedures, as drug interference can significantly distort PT and APTT results.
Testing Items
A comprehensive coagulation panel typically includes the following core parameters, each targeting a distinct portion of the hemostatic system:
- Prothrombin Time (PT) and INR: Evaluates the extrinsic and common pathways (factors VII, X, V, II, fibrinogen). The International Normalized Ratio (INR) standardizes PT results for warfarin monitoring across laboratories using the ISI of the thromboplastin reagent.
- Activated Partial Thromboplastin Time (APTT): Assesses the intrinsic and common pathways (factors XII, XI, IX, VIII, X, V, II, fibrinogen) and is sensitive to heparin, lupus anticoagulants, and intrinsic factor deficiencies.
- Thrombin Time (TT): Measures the conversion of fibrinogen to fibrin and is highly sensitive to heparin, fibrin degradation products, and hypofibrinogenemia.
- Fibrinogen (FIB): Quantitative measurement of factor I, essential for clot formation and an acute-phase reactant; low levels indicate consumption (e.g., DIC) or impaired synthesis (e.g., liver failure).
- D-Dimer: A fibrin degradation marker used to exclude venous thromboembolism (VTE) and pulmonary embolism in conjunction with clinical probability scores, and to monitor disseminated intravascular coagulation (DIC).
- Fibrin/Fibrinogen Degradation Products (FDP): Reflect global fibrinolytic activity and support DIC and thrombolytic therapy assessment.
- Activated Clotting Time (ACT): A point-of-care whole-blood assay for monitoring high-dose unfractionated heparin during extracorporeal circulation.
- Individual Clotting Factor Assays: One-stage or chromogenic assays for factors VIII, IX, XI, and others to diagnose hemophilia and related deficiencies.
- Lupus Anticoagulant and Antiphospholipid Panel: Includes mixing studies, dilute Russell viper venom time (dRVVT), and anticardiolipin/anti-β2-glycoprotein I antibodies for thrombophilia workup.
- Antithrombin III, Protein C, and Protein S: Natural anticoagulants measured in inherited thrombophilia investigation.
- Platelet Count and Function Testing: Complete blood count platelet enumeration plus aggregometry or closure-time assays to evaluate primary hemostasis.
Testing Methods
Modern coagulation laboratories employ several analytical principles, often combined on automated coagulation analyzers capable of performing clotting, chromogenic, and immunoturbidimetric assays on a single platform.
- Clot-Based (Coagulometric) Methods: PT, APTT, TT, and fibrinogen are measured by adding trigger reagents to plasma and detecting clot formation. Detection can be mechanical (magnetic or optical ball methods sensing viscosity change), photo-optical (turbidity change), or impedance-based. Mechanical methods are resistant to interference from lipemia, bilirubin, and hemolysis, whereas optical methods offer high sensitivity and enable waveform analysis.
- Immunoturbidimetric and Latex-Enhanced Immunoassays: D-dimer, FDP, and antiphospholipid antibodies are quantified using particle-enhanced immunoturbidimetry, where antigen-antibody agglutination increases measured turbidity proportional to analyte concentration.
- Chromogenic (Amidolytic) Substrate Assays: These methods use synthetic peptides that release a colored dye when cleaved by the target enzyme. They are the reference approach for antithrombin, protein C, factor VIII activity, heparin anti-Xa monitoring, and direct oral anticoagulant quantification, offering superior precision and reduced interference.
- Clauss Method for Fibrinogen: A diluted plasma thrombin clotting time that provides a functional fibrinogen concentration, considered more accurate than PT-derived fibrinogen in dysfibrinogenemia and acute-phase states.
- Mixing Studies: When PT or APTT is prolonged, patient plasma is mixed with normal pooled plasma to differentiate factor deficiency (correction) from inhibitors such as lupus anticoagulant or specific factor antibodies (no correction).
- Viscoelastic Whole-Blood Methods (ROEM-Type Analysis): Point-of-care viscoelastic testing evaluates the kinetics and strength of clot formation and lysis in whole blood, guiding targeted transfusion therapy in cardiac surgery, trauma, obstetrics, and liver transplantation.
Quality assurance encompasses daily internal quality control at multiple decision levels, participation in external quality assessment (EQA) or proficiency testing programs, verification of reagent lot performance, and adherence to ISO 15189 and relevant national standards such as GB/T or CLSI-equivalent guidance on sample handling, centrifugation, and analytical performance specifications.
Applications
Coagulation function testing supports clinical decision-making across a broad spectrum of medical disciplines:
- Preoperative Screening: PT, APTT, fibrinogen, and platelet counts are evaluated before surgery to identify bleeding risk, guide prophylactic correction, and inform surgical planning.
- Anticoagulant Therapy Monitoring: INR for warfarin, APTT or anti-Xa for unfractionated heparin, ACT for high-dose heparin in cardiopulmonary bypass, and anti-Xa or specific assays for DOACs in special circumstances.
- Bleeding Disorder Diagnosis: Identification and classification of hemophilia A and B, von Willebrand disease screening, factor deficiencies, and fibrinogen disorders.
- Thrombotic Disorder Investigation: D-dimer for VTE exclusion, lupus anticoagulant testing for antiphospholipid syndrome, and natural anticoagulant assays for inherited thrombophilia.
- DIC Diagnosis and Monitoring: Serial assessment of PT, APTT, fibrinogen, D-dimer, FDP, and platelet count using validated scoring algorithms in sepsis, trauma, obstetric complications, and malignancy.
- Liver Disease Evaluation: The liver synthesizes most clotting factors; coagulation results reflect synthetic hepatic capacity and support management of cirrhosis, acute liver failure, and transplantation.
- Obstetric Care: Detection of consumptive coagulopathy in preeclampsia, HELLP syndrome, placental abruption, and amniotic fluid embolism.
- Neonatal and Pediatric Assessment: Age-specific reference intervals account for the physiologically immature coagulation system of newborns, particularly in intensive care settings.
FAQ
Why is sodium citrate used instead of EDTA or heparin for coagulation samples?
Sodium citrate reversibly chelates calcium, allowing tests to proceed by simply re-calcifying the plasma with the assay reagent. EDTA binds calcium irreversibly and heparin directly inhibits thrombin, both of which would compromise accurate clotting time measurement.
How long can coagulation samples be stored before testing?
Generally, APTT should be analyzed within 4 hours of collection when stored at room temperature, while PT and fibrinogen may remain stable up to 24 hours refrigerated or at room temperature depending on the validated protocol. Factor assays, particularly factor VIII, have shorter stability windows, and samples for lupus anticoagulant testing can typically be stored longer at 4 °C or frozen.
What does a prolonged APTT with a normal PT suggest?
This pattern points to intrinsic pathway abnormalities: deficiencies of factors VIII, IX, XI, or XII; the presence of heparin; von Willebrand disease; or a lupus anticoagulant. A mixing study is the standard next step to distinguish a factor deficiency from an inhibitor.
Can a normal PT and APTT exclude a bleeding tendency?
No. PT and APTT only become prolonged when factor activity falls below roughly 50–60% of normal, so mild deficiencies, platelet function defects, von Willebrand disease, and fibrinolytic disorders may be present despite normal screening results. Suspicion of bleeding disorders warrants targeted additional testing.
How is INR calculated and why is it necessary?
The INR is calculated as (patient PT / geometric mean normal PT) raised to the power of the International Sensitivity Index (ISI) of the thromboplastin reagent. Because thromboplastin reagents vary in sensitivity, the INR harmonizes PT results across laboratories, which is essential for safe, consistent warfarin dose management.
Do direct oral anticoagulants interfere with routine coagulation tests?
Yes. Apixaban and rivaroxaban may modestly prolong PT and APTT in a reagent-dependent and non-linear fashion, while dabigatran prolongs APTT and thrombin time more markedly. Routine coagulation tests should not be used for DOAC quantification; specific anti-Xa or anti-IIa chromogenic assays or calibrated methods are required when drug levels must be known.
What accreditation applies to coagulation testing laboratories?
Clinical coagulation laboratories commonly operate under ISO 15189 accreditation for medical laboratories, supplemented by national standards and harmonized clinical laboratory guidelines covering pre-analytical, analytical, and post-analytical quality requirements, as well as mandatory proficiency testing participation.